ENOB Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (4 rugp. 2023 @ 22:58):

Stats
Dzisiejszy wolumen	87 289.00
Średni wolumen	254 603
Kapitalizacja rynkowa	45.38M
EPS	$-698 421 ( 2023-08-11 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.344
ATR14	$0.193 (7.42%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-23	Miller Avram	Buy	1 000 000	Common Stock
2023-10-23	Miller Avram	Buy	27 147	Option to purchase shares of common stock
2023-10-11	Miller Avram	Buy	0
2023-10-04	Hendriks Ruud	Buy	16 129	Option to purchase shares of common stock
2023-10-04	Boeren Leni	Buy	16 129	Option to purchase shares of common stock

INSIDER POWER
98.20
Last 80 transactions
Buy: 35 900 381 \| Sell: 26 846 213

Wolumen Korelacja

Długi: 0.11 (neutral)

Krótki: -0.07 (neutral)

Signal:(77.816) Neutral

Enochian Biosciences Inc Korelacja

10 Najbardziej pozytywne korelacje
UK	0.894
GAINL	0.893
MRACW	0.892
AYLA	0.891
KBSF	0.887
GRNV	0.885
ISNS	0.884
BIOL	0.879
VIH	0.874
MDWT	0.868

10 Najbardziej negatywne korelacje
BOCH	-0.92
ALPN	-0.918
BNIXU	-0.911
SGH	-0.904
NXGL	-0.903
ELTK	-0.902
AMAT	-0.892
ULTA	-0.891
MOTNU	-0.889
PEBK	-0.885

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Enochian Biosciences Inc Korelacja - Waluta/Towar

0.29
( neutral )

0.36
( neutral )

-0.02
( neutral )

0.29
( neutral )

-0.77
( moderate negative )

-0.07
( neutral )

Enochian Biosciences Inc Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-705 302

FY	2023
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-705 302

FY	2023
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$0

FY	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-2.16

Financial Reports:

No articles found.

Enochian Biosciences Inc

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.